Citi Starts Bellicum Pharmaceuticals (BLCM) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Bellicum Pharmaceuticals (BLCM) BPX-501 Moving Faster Than Many Realize, Piper Jaffray Says
July 28, 2015 8:40 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and $45 price target on Bellicum Pharmaceuticals (NASDAQ: BLCM) saying BPX-501 is moving faster than many realize.
Schimmer commented, "As we pass the halfway mark of 2015, we are refreshing our outlooks for our coverage universe. For... More
